Document is current

Article History

Accepted: 1 November 2021

First Online: 6 January 2022

Competing interests

: S.v.H. has been a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Chugai, Grünenthal, Helsinn, Hexal, Novartis, Pharmacosmos, Respicardia, Roche, Servier, Sorin, and Vifor and has received research funding from Amgen, Boehringer Ingelheim and IMI. T.K. has been a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Pharmacosmos, and Vifor and has received research support from Vifor. P.R. has been a paid consultant for and/or received honoraria payments from Abbott, AstraZeneca, Bayer, BDI, Biotronik, Conventus Congressmanagement & Marketing GmbH, CTI GmbH, Daiichi-Sankyo, Deutsche Gesellschaft für Kardiologie, Diaplan, Edwards, Elisabeth-KH Essen, Heart Institute GmbH, Herzzentrum Leipzig, Kelcon, Medizinische Ausstellungs- und Werbegesellschaft Wien, Medtronic, Novartis and Vifor. R.W. has been a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, CVRx, Daiichi, Medtronic, Novartis, Pfizer, Pharmacosmos and Servier. R.W. has received research support from Boehringer Ingelheim, Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, European Union and Medtronic. G.H. has been a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Corvia, Impulse Dynamics, Novartis, Servier, Springer and Vifor. All other authors declare no competing interests.